Compare IPCA Labs with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs WYETH LTD - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS WYETH LTD IPCA LABS/
WYETH LTD
 
P/E (TTM) x 23.2 27.7 83.5% View Chart
P/BV x 4.4 5.3 82.9% View Chart
Dividend Yield % 0.3 1.3 21.5%  

Financials

 IPCA LABS   WYETH LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-19
WYETH LTD
Mar-13
IPCA LABS/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,0421,044 99.8%   
Low Rs590818 72.1%   
Sales per share (Unadj.) Rs298.6298.6 100.0%  
Earnings per share (Unadj.) Rs35.057.2 61.1%  
Cash flow per share (Unadj.) Rs49.458.4 84.6%  
Dividends per share (Unadj.) Rs3.0017.00 17.6%  
Dividend yield (eoy) %0.41.8 20.1%  
Book value per share (Unadj.) Rs247.1249.5 99.1%  
Shares outstanding (eoy) m126.3522.72 556.1%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.73.1 87.6%   
Avg P/E ratio x23.316.3 143.3%  
P/CF ratio (eoy) x16.515.9 103.5%  
Price / Book Value ratio x3.33.7 88.5%  
Dividend payout %8.629.7 28.9%   
Avg Mkt Cap Rs m103,10821,157 487.3%   
No. of employees `00013.40.5 2,732.1%   
Total wages/salary Rs m7,874400 1,968.5%   
Avg. sales/employee Rs Th2,807.013,787.4 20.4%   
Avg. wages/employee Rs Th585.8813.0 72.1%   
Avg. net profit/employee Rs Th329.02,643.3 12.4%   
INCOME DATA
Net Sales Rs m37,7326,783 556.2%  
Other income Rs m577353 163.6%   
Total revenues Rs m38,3097,136 536.8%   
Gross profit Rs m6,9011,617 426.7%  
Depreciation Rs m1,82427 6,857.9%   
Interest Rs m1896 3,430.9%   
Profit before tax Rs m5,4651,938 282.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,042632 164.9%   
Profit after tax Rs m4,4221,301 340.0%  
Gross profit margin %18.323.8 76.7%  
Effective tax rate %19.132.6 58.5%   
Net profit margin %11.719.2 61.1%  
BALANCE SHEET DATA
Current assets Rs m23,7786,984 340.5%   
Current liabilities Rs m10,9752,056 533.8%   
Net working cap to sales %33.972.6 46.7%  
Current ratio x2.23.4 63.8%  
Inventory Days Days10499 104.5%  
Debtors Days Days6624 275.4%  
Net fixed assets Rs m20,368244 8,337.1%   
Share capital Rs m253227 111.2%   
"Free" reserves Rs m30,9715,441 569.2%   
Net worth Rs m31,2245,668 550.9%   
Long term debt Rs m1,40925 5,634.0%   
Total assets Rs m45,5077,901 576.0%  
Interest coverage x30.0353.3 8.5%   
Debt to equity ratio x00 1,022.7%  
Sales to assets ratio x0.80.9 96.6%   
Return on assets %10.116.5 61.3%  
Return on equity %14.222.9 61.7%  
Return on capital %17.334.0 50.9%  
Exports to sales %45.90.2 21,025.0%   
Imports to sales %16.636.3 45.7%   
Exports (fob) Rs m17,30815 116,948.6%   
Imports (cif) Rs m6,2662,465 254.2%   
Fx inflow Rs m17,30815 113,871.1%   
Fx outflow Rs m6,2662,677 234.1%   
Net fx Rs m11,042-2,662 -414.8%   
CASH FLOW
From Operations Rs m4,923923 533.2%  
From Investments Rs m-1,563317 -493.2%  
From Financial Activity Rs m-1,832-481 380.9%  
Net Cashflow Rs m1,528759 201.3%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 7.2 351.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 30.4 57.2%  
Shareholders   36,892 21,978 167.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - CADILA HEALTHCARE COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS